Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 8

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 8
---
4”) agonist that can stimulate the human body’s innate immune response to prevent and treat disease. Our current Gemini based programs consist of: Gemini -AKI, which is being developed for the prevention of AKI; Gemini -CKD 1 for the treatment of CKD; Gemini -PSI, which is being developed for the prevention of PSI; and GEM -PBIas a prevention of infection in severe burn patients requiring hospitalization (our “Product Candidates”). Revelation’s pipeline is summarized in the figure below: The Gemini Platform Our current therapeutic candidates are all based on our proprietary Gemini formulation of PHAD ®, a synthetic version of monophosphoryl lipid A (“MPLA”), that is known to stimulate TLR4. Stimulation of TLR4 via Gemini leads to a more controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to a lipopolysaccharide, a traditional TLR4 agonist. This “Immunostimulatory Preconditioning” with Gemini prepares the body to better guard against a rapid upregulation of multiple pro -inflammatoryand microbial gene products and proteins, such as pathogen -associatedmolecular patterns (“PAMPS”) and damage -associatedmolecular patterns (“DAMPS”) (damage -associatedmolecular proteins) (Zwirner 2017, Hernandez 2019, Ismaeli 2002). Modulated activities may include stimulation and recruitment of infection fighting immune cells, reduction of inflammation, and/or regulation of inflammation depending on the degree and nature of the stimulation, which enables the multiple potential product candidates in development. Figure 1: Interaction of PHAD with TLR4 2 Gemini-AKI The Gemini -AKIprogram is being developed as a potential therapy for the prevention of AKI due to external stress or insult (e.g. surgical procedure, chemotherapy toxicity). We believe immunologic preconditioning with Gemini prepares the body to handle biologic stress by redirecting the body’s immune system to have an attenuated response to the stress. Preclinical studies have demonstrated that preconditioning with PHAD significantly reduces the severity and duration of AKI following an ischemia of the kidney. Additional data from these preclinical studies have been accepted for presentation at The International Conference on Advances in Critical Care Nephrology on March 12, 2024. During 2024 we conducted a Phase 1 clinical study. safety and biomarker activity data from our Phase 1